FrancophonIA/ELRC3.0 huggingface dataset:
English: Dilution: Carefully insert the needle of a syringe into the vial and withdraw the required volume.
Croatian: Razrjeđivanje: Pažljivo umetnite iglu štrcaljke u bočicu te izvucite potreban volumen.
English: In the presence of coagulopathy, the oral administration of the chelating agent Dimercaptosuccinic Acid Succimer (DCI) 10 mg/kg or 350 mg/m2 every 8 hours during 5 days and then every 12 hours during 2 weeks is recommended.
Croatian: Ako je prisutna koagulopatija, preporučuje se peroralna primjena kelirajućeg agensa sukcimera dimerkaptosukcinilne kiseline (DCI) 10 mg/kg ili 350 mg/m2 svakih 8 sati tijekom 5 dana i potom svakih 12 sati tijekom 2 tjedna.
English: Multicentre trial N=40
Croatian: Multicentrično ispitivanje N = 40
English: Biotransformation The metabolism of arsenic trioxide involves oxidation of arsenious acid (AsIII), the active species of arsenic trioxide, to arsenic acid (AsV), as well as oxidative methylation to monomethylarsonic acid (MMAV) and dimethylarsinic acid (DMAV) by methyltransferases, primarily in the liver.
Croatian: Metabolizam arsenova trioksida uključuje oksidaciju arsenične kiseline (AsIII), aktivnog oblika arsenova trioksida u arsenovu kiselinu (AsV), kao i oksidativnu metilaciju u monometilarsoničnu kiselinu (MMAV) i dimetilarseničnu kiselinu (DMAV) putem metiltransferaza, prvenstveno u jetri.
English: The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.
Croatian: Stopa odgovora drugih podtipova akutne mijelogene leukemije na arsenov trioksid nije proučavana.
English: In order to prevent the development of the APL differentiation syndrome during induction treatment, prednisone (0.5 mg/kg body weight per day throughout induction treatment) may be administered from day 1 of TRISENOX application to the end of induction therapy in APL patients.
Croatian: Radi sprječavanja razvoja sindroma diferencijacije APL-a tijekom indukcijskog liječenja, može se primjenjivati prednizon (0,5 mg/kg tjelesne težine na dan tijekom indukcijskog liječenja) od 1. dana primjene TRISENOXA do kraja indukcijske terapije u bolesnika s APL-om.
English: QT interval prolongation
Croatian: Produljenje QT intervala
English: 54 days
Croatian: 54 dana
English: If QTc prolongation does not recur within 7 days of restarting treatment at the reduced dose, treatment with TRISENOX can be resumed at 0.11 mg/kg body weight per day for a second week.
Croatian: Ako ne nastupi produljenje QTc intervala unutar 7 dana od ponovnog početka liječenja pri smanjenoj dozi, liječenje TRISENOXOM može se nastaviti u dozi od 0,11 mg/kg tjelesne težine na dan tijekom drugog tjedna.
English: Total arsenic accumulates mainly in the liver, kidney, and heart and, to a lesser extent, in the lung, hair, and nails.
Croatian: Ukupni arsen akumulira se uglavnom u jetri, bubrezima i srcu te u manjem opsegu u plućima,
English: At last follow-up, 6 of 12 patients in the single institution study were alive with a median follow-up time of 28 months (range 25 to 29).
Croatian: Prilikom zadnje kontrole, preživjelo je 6 od 12 bolesnika u monocentričnom ispitivanju s medijanom vremena kontrole od 28 mjeseci (raspon 25 to 29).
English: Arsenic trioxide also causes damage or degradation of the fusion protein promyelocytic leukaemia/retinoic acid receptor-alpha (PML/RAR alpha).
Croatian: Arsenov trioksid također uzrokuje oštećenje ili degradaciju fuzijskog proteina alfa-receptora promijelocitne leukemije / retinoične kiseline (PML/RAR alfa).
English: As soon as bilirubin and/or SGOT and/or alkaline phosphatase are decreased to below 4 times the normal upper level, treatment with TRISENOX should be resumed at 50 % of the previous dose during the first 7 days.
Croatian: Čim se vrijednosti bilirubina i/ili SGOT-a i/ili alkalne fosfataze smanje ispod 4-struke vrijednosti gornje granice normale, liječenje TRISENOXOM potrebno je nastaviti s 50% prethodne doze tijekom prvih 7 dana.
English: Clinically unstable APL patients are especially at risk and will require more frequent monitoring of electrolyte and glycaemia levels as well as more frequent haematologic, hepatic, renal and coagulation parameter tests.
Croatian: Klinički nestabilni bolesnici s APL-om su posebice ugroženi te će zahtijevati češći nadzor razina elektrolita i glikemije kao i češće hematološke pretrage, jetrene probe te testiranja parametara koagulacije i bubrega.
English: Patients with risk factors of QTc prolongation or risk factors of torsade de pointes should be monitored with continuous cardiac monitoring (ECG).
Croatian: Bolesnike koji su pod rizikom od produljenja QTc intervala ili od torsade de points mora se nadzirati neprekidnim praćenjem kardiološkog statusa (EKG).
English: • medicines to treat psychosis (loss of contact with reality, e.g. thioridazine)
Croatian: • lijekove za liječenje psihoze (gubitak dodira sa stvarnošću, primjerice tioridazin)
English: In the case of the reappearance of symptoms TRISENOX should be reduced to the previous dosage.
Croatian: U slučaju ponovne pojave simptoma potrebno je sniziti TRISENOX na prethodnu dozu.
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8 °C, unless dilution has taken place in controlled and validated aseptic conditions.
Croatian: Ako se ne upotrijebi odmah, vrijeme čuvanja u uporabi i uvjeti prije uporabe odgovornost su korisnika te inače ne bi smjeli biti dulji od 24 sata pri 2-8 °C, osim kad se razrjeđivanje provodi u kontroliranim i validiranim aseptičkim uvjetima.
English: At the first signs that could suggest the syndrome (unexplained fever, dyspnoea and/or weight gain, abnormal chest auscultatory findings or radiographic abnormalities), treatment with TRISENOX must be temporarily discontinued and high-dose steroids (dexamethasone 10 mg intravenously twice a day) must be immediately initiated, irrespective of the leukocyte count and continued for at least 3 days or longer until signs and symptoms have abated.
Croatian: Na prve znakove koji bi mogli ukazivati na sindrom (neobjašnjiva vrućica, dispneja i/ili porast tjelesne težine, abnormalni nalazi auskultacije prsnog koša ili radiografske abnormalnosti), mora se privremeno prekinuti liječenje TRISENOXOM i mora se odmah započeti s visokim dozama steroida (deksametazon 10 mg intravenski dvaput na dan) neovisno o broju leukocita, i nastaviti s liječenjem najmanje 3 dana ili dulje sve dok se simptomi i znakovi ne povuku.
English: Single use only
Croatian: Samo za jednokratnu primjenu
English: In the multicentre study 27 of 40 patients were alive with a median follow-up time of 16 months (range 9 to 25).
Croatian: U monocentričnom ispitivanju preživjelo je 27 od 40 bolesnika s medijanom vremena kontrole od 16 mjeseci (raspon 9 to 25).
English: Hyperleucocytosis was never treated with additional chemotherapy and resolved on continuation of TRISENOX.
Croatian: Hiperleukocitoza nikad nije bila liječena dodatnom kemoterapijom te se povukla pri nastavku liječenja TRISENOXOM.
English: Patients who reach an absolute QT interval value > 500 msec must be reassessed and immediate action must be taken to correct concomitant risk factors, if any, while the risk/benefit of continuing versus suspending TRISENOX therapy must be considered.
Croatian: Bolesnici koji postignu apsolutnu vrijednost QT intervala > 500 ms moraju se ponovno podvrgnuti pregledu te je potrebno hitno djelovati kako bi se korigirali istodobni čimbenici rizika, ako postoje, te je potrebno razmotriti omjer rizika/dobrobiti nastavka liječenja naspram prekida terapijom TRISENOXA.
English: Treatment with arsenic trioxide has been associated with the development of hyperleucocytosis (≥ 10 x 103/μl) in some relapsed/refractory APL patients.
Croatian: Liječenje arsenovim trioksidom povezano je razvojem hiperleukocitoze (≥ 10 x 103/μl) u nekih bolesnika s APL-om koji je u fazi relapsa/refraktoran na liječenje.
English: • medicines for depression (e.g. amitriptyline)
Croatian: • lijekove za depresiju (primjerice, amitriptilin)
English: After dilution, if not used immediately, storage times and conditions before use are the responsibility of your doctor, pharmacist or nurse and would normally not be longer than 24 hours at 2 to 8 ºC, unless dilution has taken place in a sterile environment.
Croatian: Nakon razrjeđivanja, ako se ne upotrijebi odmah, vrijeme čuvanja i uvjeti prije uporabe odgovornost su Vašeg liječnika, ljekarnika ili medicinske sestre te inače ne bi smjeli biti dulji od 24 sata pri temperaturi od 2 do 8 °C, osim ako se razrjeđivanje provodi u sterilnim uvjetima.
English: In your first treatment cycle, you may be treated every day up to 60 days at most or until your doctor determines that your disease is better.
Croatian: U Vašem prvom ciklusu liječenja možda ćete dobivati TRISENOX svaki dan do 60 dana najviše ili dok liječnik ne utvrdi da Vam je bolje.
English: APL is a unique type of myeloid leukaemia, a disease in which abnormal white blood cells and abnormal bleeding and bruising occur.
Croatian: Promijelocitna leukemija je jedinstveni tip mijeloidne leukemije, bolesti kod koje se javljaju poremećene bijele krvne stanice i neuobičajena krvarenja i stvaranje modrica.
English: Because TRISENOX can harm nursing infants, do not breast-feed while on TRISENOX.
Croatian: S obzirom da TRISENOX može naškoditi dojenčetu, nemojte dojiti dijete dok se liječite
English: Investigations Alanine amino transferase increased
Croatian: Pretrage porast alanin aminotransferaze
English: Medicinal products known to cause QT/QTc interval prolongation, hypokalaemia or hypomagnesaemia
Croatian: Lijekovi za koje je poznato da uzrokuju produljenje QT/QTc intervala, hipokalemiju ili hipomagnezijemiju
English: TRISENOX has no or negligible influence on the ability to drive and use machines.
Croatian: TRISENOX ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: One patient (receiving multiple, concomitant medicinal products, including amphotericin B) had asymptomatic torsade de pointes during induction therapy for relapsed APL with arsenic trioxide.
Croatian: Jedna je bolesnica (koja je primala više lijekova istodobno, uključujući i amfotericin B) imala asimptomatsku torsade de pointes tijekom indukcijske terapije arsenovim trioksidom za relaps APL-a.
English: Electrocardiogram (ECG) abnormalities
Croatian: Odstupanja elektrokardiograma (EKG-a)
English: PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate).
Croatian: Koncentrat za otopinu za infuziju (sterilni koncentrat).
English: Forty-four per cent of relapsed/refractory APL patients experienced symptoms that could be associated with neuropathy; most were mild to moderate and were reversible upon cessation of treatment with TRISENOX.
Croatian: Četrdeset i četiri posto bolesnika s APL-om koji je bio u fazi relapsa/refraktoran na liječenje imalo je simptome koji su se mogli povezati s neuropatijom; većina ih je bila blaga do umjerena te su postali reverzibilni nakon prekida liječenja TRISENOXOM.
English: Limited reproductive toxicity studies of arsenic trioxide in animals indicate embryotoxicity and teratogenicity (neural tube defects, anophthalmia and microphthalmia) at administration of 1-10 times the recommended clinical dose (mg/m2).
Croatian: Ograničena ispitivanja reproduktivne toksičnosti arsenova trioksida na životinjama ukazuju na embriotoksičnost i teratogenost (oštećenja neuralne cijevi, anoftalmiju i mikroftalmiju) pri primjeni 110 puta većih doza od preporučene kliničke doze (mg/m2).
English: Arsenic trioxide causes morphological changes and deoxyribonucleic acid (DNA) fragmentation characteristic of apoptosis in NB4 human promyelocytic leukaemia cells in vitro.
Croatian: Arsenov trioksid uzrokuje morfološke promjene i fragmentaciju deoksiribonukleinske kiseline (DNK) karakteristične za apoptozu u humanim NB4 stanicama promijelocitne leukemije in vitro.
English: In your first treatment cycle, you may be treated every day up to 50 days at most or until your doctor determines that your disease is better.
Croatian: U Vašem prvom ciklusu liječenja možda ćete dobivati TRISENOX svaki dan do najviše 50 dana ili dok liječnik ne utvrdi da Vam je bolje.
English: Tell your doctor or nurse straight away if you notice the following side effects, as these may be signs of a severe condition called “differentiation syndrome”, which might be fatal: - difficulty in breathing - coughing - chest pain - fever
Croatian: Odmah obavijestite svog liječnika ili medicinsku sestru ako primijetite bilo koju od sljedećih nuspojava jer one mogu biti znakovi ozbiljnog stanja zvanog „sindrom diferencijacije“ koji može biti smrtonosan:
English: One patient treated under a compassionate use program died from cerebral infarct due to leucocytosis, following treatment with chemotherapeutic medicinal products to lower WBC count.
Croatian: Jedan bolesnik liječen u programu milosrdnog davanja lijeka umro je od moždanog infarkta zbog leukocitoze nakon liječenja kemoterapeuticima za snižavanje razine leukocita.
English: The experience in patients with severe hepatic impairment is insufficient to determine if dose adjustment is required.
Croatian: Iskustvo u bolesnika s teškim oštećenjem bubrega nedovoljno je za određivanje je li potrebna prilagodba doze.
English: If symptoms suggestive of serious acute arsenic toxicity (e.g. convulsions, muscle weakness and confusion) appear, TRISENOX must be immediately discontinued and chelating therapy with penicillamine at a daily dose ≤ 1 g per day may be considered.
Croatian: Ako se pojave simptomi koji ukazuju na ozbiljne akutne toksične reakcije arsena (primjerice, konvulzije, slabosti u mišićima i konfuzija), mora se odmah prekinuti primjenu TRISENOXA i razmotriti primjenu kelirajućih agensa s penicilaminom pri dnevnoj dozi od ≤ 1 g na dan.
English: Patients in the first study received a median dose of 0.16 mg/kg/day of TRISENOX (range 0.06 to 0.20 mg/kg/day) and patients in the multicentre study received a fixed dose of 0.15 mg/kg/day.
Croatian: Bolesnici u prvom ispitivanju primili su medijan doze TRISENOXA od 0,16 mg/kg/dan (raspon od 0,06 do 0,20 mg/kg/dan) a bolesnici u multicentričnom ispitivanju primili su fiksnu dozu od 0,15 mg/kg/dan.
English: The arsenic in TRISENOX passes into breast milk.
Croatian: Arsen u TRISENOXU se izlučuje u majčino mlijeko.
English: Cytotoxic: handle with caution
Croatian: Citotoksično: rukovati s oprezom
English: Additional information about QT prolonging medicinal agents, is provided in section 4.4.
Croatian: Dodatne informacije o lijekovima koji produljuju QT interval nalaze se u dijelu 4.4.
English: 2-Year disease-free survival (DFS)
Croatian: 2-godišnje preživljenje bez bolesti (engl. disease-free survival, DFS)
English: • Relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.
Croatian: • akutnom promijelocitnom leukemijom (APL) koja je u fazi relapsa/refraktorna na liječenje (prethodno liječenje trebalo je uključivati retinoatnu kiselinu i kemoterapiju) a koja je karakterizirana prisutnošću translokacije t(15;17) i/ili prisutnošću gena za alfa receptor za promijelocitnu leukemiju/retinoatnu kiselinu (PML/RAR-alfa).
English: This medicine must not be used if you notice foreign particulate matter or if the solution is discoloured.
Croatian: Ovaj lijek se ne smije upotrijebiti ako primijetite strane čestice ili ako je otopina promijenila boju.
English: QT prolongation can lead to a torsade de pointes-type ventricular arrhythmia, which can be fatal.
Croatian: Produljenje QT intervala može uzrokovati ventrikularnu aritmiju tipa torsade de points, koja može biti smrtonosna.
English: If you are able to become pregnant, you must use effective birth control during treatment with TRISENOX.
Croatian: Ako biste mogli zatrudnjeti, morate koristiti učinkovitu metodu kontrole začeća tijekom liječenja
English: - The other ingredients are sodium hydroxide, hydrochloric acid and water for injections.
Croatian: - Drugi sastojci su natrijev hidroksid, kloridna kiselina i voda za injekcije.
English: Complete remission (CR) was defined as the absence of visible leukaemic cells in the bone marrow and peripheral recovery of platelets and white blood cells.
Croatian: Potpuna remisija (CR) bila je definirana kao odsutnost vidljivih leukemičnih stanica u koštanoj srži i periferni oporavak trombocita i leukocita.
English: TRISENOX must be administered intravenously at a fixed dose of 0.15 mg/kg/day given daily until complete remission is achieved (less than 5 % blasts present in cellular bone marrow with no evidence of leukaemic cells).
Croatian: TRISENOX se mora primjenjivati intravenski pri fiksnoj dozi od 0,15 mg/kg/dan, svaki dan, sve dok se ne postigne potpuna remisija (manje od 5% blasta prisutnih u stanicama koštane srži bez dokaza leukemičnih stanica).
English: The following undesirable effects have been reported in the APL0406 study in newly diagnosed patients and in clinical trials and/or post-marketing experience in relapsed/refractory APL patients.
Croatian: Sljedeće nuspojave prijavljene su u ispitivanju APL0406 u novodijagnosticiranih bolesnika te u kliničkim ispitivanjima i/ili nakon stavljanja lijeka u promet u bolesnika s APL-om koji je bio u fazi relapsa/refraktoran na liječenje.
English: Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block.
Croatian: Arsenov trioksid može uzrokovati produljenje QT intervala te potpuni atrioventrikularni blok.
English: The use of TRISENOX in patients on dialysis has not been studied.
Croatian: Primjena TRISENOXA u bolesnika na dijalizi nije proučavana.
English: Patients with newly diagnosed APL confirmed by the presence of t(15; 17) or PML-RARα by RT-PCR or micro speckled PML nuclear distribution in leukaemic cells were included.
Croatian: Uključeni su bili bolesnici s novodijagnosticiranim APL-om koji je bio potvrđen prisutnošću translokacije t(15; 17) ili PML-RARα metodom RT-PCR ili mikro raspršenom nuklearnom distribucijom PML-a u leukemijskim stanicama.
English: TRISENOX must not be mixed with, or infused through the same tube with other medicines.
Croatian: TRISENOX se ne smije miješati ili davati infuzijom kroz istu cjevčicu s drugim lijekovima.
English: During TRISENOX treatment, 14 of the 52 patients in the APL studies in the relapsed setting had one or more symptoms of APL differentiation syndrome, characterised by fever, dyspnoea, weight gain, pulmonary infiltrates and pleural or pericardial effusions, with or without leucocytosis (see section 4.4).
Croatian: Tijekom liječenja TRISENOXOM, 14 od 52 bolesnika s APL-om u fazi relapsa imali su jedan ili više simptoma sindroma diferencijacije APL-a, koji karakteriziraju vrućica, dispneja, porast tjelesne težine, plućni infiltrati i pleuralni ili perikardijalni izljevi, s leukocitozom ili bez nje (vidjeti dio 4.4).
English: Any unused medicinal product, any items that come into contact with the product or waste material must be disposed of in accordance with local requirements.
Croatian: Neiskorišteni lijek, bilo koji predmet koji dolazi u dodir s lijekom ili otpadni materijal potrebno je zbrinuti sukladno nacionalnim propisima.
English: Arsenic compounds induce chromosomal aberrations and morphological transformations of mammalian cells in vitro and in vivo.
Croatian: Spojevi arsena induciraju kromosomske aberacije i morfološke promjene u stanicama sisavaca in vitro te in vivo.
English: In post marketing experience, a differentiation syndrome, like retinoic acid syndrome, has also been reported for the treatment of malignancies other than APL with TRISENOX.
Croatian: Prema iskustvu nakon stavljanja lijeka u promet, sindrom diferencijacije, poput sindroma retinoatne kiseline, bio je zabilježen i kada su TRISENOXOM liječene druge maligne bolesti osim APL-a.
English: Caution is advised when TRISENOX is co-administered with other medicinal products known to cause QT/QTc interval prolongation such as macrolide antibiotics, the antipsychotic thioridazine, or medicinal products known to cause hypokalaemia or hypomagnesaemia.
Croatian: Preporučuje se oprez kad se TRISENOX primjenjuje istodobno s drugim lijekovima za koje se zna da uzrokuju produljenje QT/QTc intervala poput makrolidnih antibiotika, antipsihotika tioridazina ili lijekovima za koje se zna da uzrokuju hipokalemiju ili hipomagnezijemiju.
English: Each pack contains 10 ampoules.
Croatian: Jedno pakiranje sadrži 10 ampula.
English: Patients at risk of B1 deficiency should be closely monitored for signs and symptoms of encephalopathy after arsenic trioxide initiation.
Croatian: Bolesnike pod rizikom od manjka vitamina B1 mora se pažljivo pratiti nakon početka primjene arsenovog trioksida zbog eventualnih znakova i simptoma encefalopatije.
English: In a follow-up treatment after consolidation, 7 patients in the single institution study and 18 patients in the multicentre study received further maintenance therapy with TRISENOX.
Croatian: U kontrolnom praćenju nakon konsolidacije, 7 je bolesnika u monocentričnom i 18 u multicentričnom ispitivanju primilo nastavak terapije održavanja TRISENOXOM.
English: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free'.
Croatian: Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po dozi, tj. zanemarive količine natrija.
English: ECG and electrolyte monitoring recommendations
Croatian: Preporuke za praćenje EKG-a i nadzor nad elektrolitima
English: Nervous system disorders Paraesthesia
Croatian: Poremećaji živčanog sustava parestezija
English: TRISENOX dose, mg/kg/day (median, range) Complete remission Time to bone marrow remission (median)
Croatian: Doza TRISENOXA, mg/kg/dan (medijan, raspon) Potpuna remisija
English: In newly diagnosed patients with low to intermediate risk APL, differentiation syndrome was observed in 19 % including 5 severe cases.
Croatian: U novodijagnosticiranih bolesnika s APL-om niskog do srednjeg rizika primijećen je sindrom diferencijacije u njih 19% uključujući 5 teških slučajeva.
English: In newly diagnosed and relapsed/refractory APL patients who develop sustained leucocytosis after initiation of therapy, hydroxyurea should be administered.
Croatian: U bolesnika s novodijagnosticiranim APL-om i APL-om koji je u fazi relapsa/refraktoran na liječenje, a koji su razvili trajnu leukocitozu nakon započinjanja terapije potrebno je primijeniti hidroksiureju.
English: In newly diagnosed patients, with low to intermediate risk APL, QTc prolongation was observed in 15.6 %.
Croatian: U novodijagnosticiranih bolesnika s APL-om niskog do srednjeg rizika primijećeno je produljenje QTc intervala u njih 15,6%.
English: Baseline white blood cell (WBC) counts did not correlate with development of leucocytosis on study, and WBC counts during consolidation therapy were not as high as during induction.
Croatian: Početne vrijednosti leukocita nisu korelirale s razvojem leukocitoze u ispitivanju, a broj leukocita tijekom konsolidacijske terapije nije bio tako visok kao tijekom indukcije.
English: Three patients from the single institution study and 15 patients from the multicentre study had stem cell transplants after completing TRISENOX.
Croatian: Tri bolesnika iz monocentričnog ispitivanja i 15 bolesnika iz multicentričnog ispitivanja podvrgnuli su se transplantaciji matičnih stanica nakon dovršetka liječenja TRISENOXOM.
English: Cytogenetic confirmation of conversion to a normal genotype and reverse transcriptase - polymerase chain reaction (RT-PCR) detection of PML/RAR conversion to normal are shown in table 5 below.
Croatian: Citogenetska potvrda konverzije u normalni genotip i detekcija konverzije PML/RARα u normalnu reakcijom obrnute transkriptaze - lančane polimeraze (RT-PCR), prikazane su u tablici 5 u nastavku.